Rowe JM - Search Results

1

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.

Gönen M, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J, Ketterling RP, Fernandez H, Rowe JM, Tallman MS, Melnick A, Levine RL, Paietta E. Gönen M, et al. Among authors: rowe jm. Blood. 2012 Sep 13;120(11):2297-306. doi: 10.1182/blood-2012-02-414425. Epub 2012 Aug 1. Blood. 2012. PMID: 22855599 Free PMC article. Clinical Trial.

2

Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.

Dutcher JP, Eudey L, Wiernik PH, Paietta E, Bennett JM, Arlin Z, Kellermeyer R, Rowe J, O'Connell M, Oken M, et al. Dutcher JP, et al. Among authors: rowe j. Leukemia. 1992 Aug;6(8):770-5. Leukemia. 1992. PMID: 1379312 Clinical Trial.

3

Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia.

Rowe JM, Chang AY, Bennett JM. Rowe JM, et al. Blood. 1988 Apr;71(4):992-6. Blood. 1988. PMID: 3162695 Free article.

4

Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.

Tallman MS, Gray R, Bennett JM, Variakojis D, Robert N, Wood WC, Rowe JM, Wiernik PH. Tallman MS, et al. Among authors: rowe jm. J Clin Oncol. 1995 Jul;13(7):1557-63. doi: 10.1200/JCO.1995.13.7.1557. J Clin Oncol. 1995. PMID: 7602344 Clinical Trial.

5

A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).

Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH. Rowe JM, et al. Blood. 1995 Jul 15;86(2):457-62. Blood. 1995. PMID: 7605984 Free article. Clinical Trial.

6

Acute promyelocytic leukemia: a paradigm for differentiation therapy with retinoic acid.

Tallman MS, Rowe JM. Tallman MS, et al. Among authors: rowe jm. Blood Rev. 1994 Jun;8(2):70-8. doi: 10.1016/s0268-960x(05)80010-4. Blood Rev. 1994. PMID: 7950477 Review. No abstract available.

7

The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study.

Paietta E, Andersen J, Gallagher R, Bennett J, Yunis J, Cassileth P, Rowe J, Wiernik PH. Paietta E, et al. Leukemia. 1994 Jul;8(7):1108-12. Leukemia. 1994. PMID: 8035602

8

Morphologic classification of acute myeloid leukemia: concordance among Eastern Cooperative Oncology Group investigators: a comment.

Bennett JM, Cassileth PA, Paietta E, Rowe JM, Wiernik PH. Bennett JM, et al. Among authors: rowe jm. Leukemia. 1996 Aug;10(8):1365. Leukemia. 1996. PMID: 8709645 No abstract available.

9

Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?

Bennett CL, Golub R, Waters TM, Tallman MS, Rowe JM. Bennett CL, et al. Among authors: rowe jm. Cancer Invest. 1997;15(3):227-36. doi: 10.3109/07357909709039720. Cancer Invest. 1997. PMID: 9171857 Clinical Trial.

10

Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged?

Rowe JM, Tallman MS. Rowe JM, et al. Blood. 1997 Sep 15;90(6):2121-6. Blood. 1997. PMID: 9310463 Free article. Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

492 results

Search Page

Filters